Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Concurrent Chemoradiation
Treatment for Esophageal cancer
Typical Dosage: Chemotherapy: e.g., Cisplatin 75 mg/m2 D1, 5-FU 1000 mg/m2/day D1-4 (every 3 weeks for 2-3 cycles) OR Carboplatin AUC 2 + Paclitaxel 50 mg/m2 weekly. Radiation: 50.4 Gy in 28 fractions.
Effectiveness
85%
Safety Score
25%
Clinical Trials
196
Participants
30K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
Chemotherapy: e.g., Cisplatin 75 mg/m2 D1, 5-FU 1000 mg/m2/day D1-4 (every 3 weeks for 2-3 cycles) OR Carboplatin AUC 2 + Paclitaxel 50 mg/m2 weekly. Radiation: 50.4 Gy in 28 fractions.
Time to Effect
1-2 months
Treatment Duration
5-6 weeks
Evidence Quality
HIGHNumber Needed to Treat (NNT)
7(Treat 7 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$15,000
Monitoring:$50,000
Side Effect Mgmt:$15,000
Total Annual:$80,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODQALYs Gained
2
Outcome-Based Costs
Cost per Responder
$114,285.71
Cost per Remission
$266,666.67
Concurrent Chemoradiation Outcomes
for Esophageal cancer
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
7 active trials recruiting for Concurrent Chemoradiation in Esophageal cancer
Adaptive Neoadjuvant Therapy for Esophageal Cancer
NCT06990178ENROLLING BY INVITATIONNA
43 participants
INTERVENTIONAL
Shenzhen, China
Started: Mar 1, 2028
Chemoradiation Versus Esophagectomy for Locally Advanced Esophageal Cancer
NCT02972372RECRUITINGNA
196 participants
INTERVENTIONAL
Anyang, China +1 more
Started: Nov 1, 2016
Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.
NCT06452602RECRUITINGPHASE2
60 participants
INTERVENTIONAL
Tianjin, China
Started: Jun 19, 2024
Neoadjuvant Chemoimmunotherapy or Chemoradiotherapy in ESCC
NCT07385664NOT YET RECRUITINGPHASE2
66 participants
INTERVENTIONAL
Hangzhou, China
Started: Jan 28, 2026
Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma
NCT04135664RECRUITINGPHASE3
176 participants
INTERVENTIONAL
Nanchang, China +5 more
Started: Sep 1, 2019
Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age
NCT06354218RECRUITINGPHASE2
50 participants
INTERVENTIONAL
Nanjing, China
Started: Dec 1, 2023
Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer
NCT06430658RECRUITINGPHASE2
90 participants
INTERVENTIONAL
Beijing, China
Started: Apr 1, 2024
Completed Clinical Trials
4 completed trials for Concurrent Chemoradiation in Esophageal cancer
Radiation Dose Escalation in Esophageal Cancer
NCT03082586COMPLETEDNA
31 participants
INTERVENTIONAL
Shanghai, China
Started: Nov 20, 2016
PET/CT-directed Hyperfractionated Radiation Dose Escalation in Esophageal Cancer
NCT03113214COMPLETEDNA
27 participants
INTERVENTIONAL
Shanghai, China
Started: Feb 2, 2017
Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer
NCT01691625COMPLETEDNA
50 participants
INTERVENTIONAL
Beijing, China
Started: Sep 1, 2012
Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age
NCT06048913COMPLETEDPHASE2
56 participants
INTERVENTIONAL
Nanjing, China
Started: Dec 1, 2020
Showing 20 of 208 total trials